GC Cell and Checkpoint Therapeutics Target New Frontiers In Cancer Therapy

GC Cell and Checkpoint Therapeutics have joined forces in a groundbreaking partnership aimed at unlocking the synergistic potential of cosibelimab, Checkpoint’s innovative anti-PD-L1 antibody with dual action mechanisms, and GC Cell’s Immuncell-LC, a pioneering autologous Cytokine Induced Killer (CIK) T cell therapy comprising cytotoxic T lymphocytes and natural killer T cells.

Their collaboration will commence with in-depth in vitro studies to assess how these therapies synergize in destroying cancer cells. Promising initial findings could lay the groundwork for subsequent in vivo investigations and clinical trials. Extensive research underscores the expected synergy between cosibelimab’s antibody-dependent cellular cytotoxicity (ADCC) mechanism and Immuncell-LC’s robust autologous CIK T cell response, promising a more effective harnessing of the immune system to target and eliminate cancerous cells.

James Park, CEO of GC Cell, remarked "This collaboration is a pivotal step towards significant technological collaborations. The integration of cosibelimab's clinical efficacy and safety profile with our Immuncell-LC could set new therapeutic standards in immuno-oncology. We are optimistic that this partnership will lead to effective commercial licensing or joint development in the future."

James F. Oliviero, CEO of Checkpoint Therapeutics, also said that "Both cosibelimab, with its dual mechanism of action, and Immuncell-LC show great promise as potential immuno-oncologic therapies. We are pleased to work in collaboration with GC Cell to determine if using the two therapies in combination may offer even greater potential benefits than being used singly.”